About the Epilepsy Neurogenetics Initiative (ENGIN)

The Epilepsy Neurogenetics Initiative (ENGIN) at Children’s Hospital of Philadelphia (CHOP) integrates genetic testing into the diagnosis and treatment of children with difficult-to-treat or unexplained epilepsies, and provides access to expert care for children with genetic epilepsy syndromes and other genetic neurodevelopmental disorders. We combine cutting-edge clinical care and advanced genetic testing with innovative research to identify the genetic variants causing a child’s epilepsy and develop an individualized approach to treatment and management.

When your child is seen in our ENGIN clinic, they will be treated by a core care team that includes an attending pediatric neurologist and genetic counselor who specialize in genetic epilepsies and neurogenetic disorders, as well as physical and occupational therapists. Depending on your child’s personalized treatment plan, they may also see neurosurgeons, research coordinators, cardiologists, gastroenterologists, neuro-ophthalmologists, social workers, psychologists and other specialists, all of whom have experience treating children with genetic epilepsies.

What we offer

Our team of neurogenetics experts partners with families, primary care physicians and referring physicians to provide the best care available. We offer:

  • Unparalleled access to genetic testing
  • An extensive team that includes neurogeneticists, genetic counselors, pediatric epilepsy experts, a neurosurgeon and therapists
  • Individualized treatment plans
  • Access to the comprehensive care and related specialists necessary to manage the full range of issues associated with epilepsy

Establishing a genetic diagnosis for a child’s epilepsy can:

  • Provide a family answers as to why their child developed epilepsy, the disease prognosis and the risk of recurrence in other family members
  • Inform treatment and management
  • Allow the family to connect with other families of children with the same diagnosis
  • Enable research to better understand disease mechanisms and develop precision treatments
  • Reduce or eliminate the need for additional invasive diagnostic testing

Translating research to treatment

ENGIN brings together clinical care and research components that seek to translate research directly into the development of new therapies that will benefit children around the world. Our team is made up of experts who are leaders in the field of epilepsy genetics and are pioneering research into the discovery of new genetic causes of epilepsy, understanding how genetic variants can lead to seizures, and the development of individualized gene-specific treatments.

Children’s Hospital of Philadelphia recognizes the importance of research in this field and what it can do for children with epilepsy and their families. In an effort to continually elevate care for children with epilepsy and other neurogenetic disorders, CHOP has made a significant investment in our Neurogenetics and Epilepsy programs. Our Epilepsy Neurogenetics Initiative was designated a Frontier Program by Children's Hospital of Philadelphia in 2019. Frontier Programs are unique, cutting-edge programs that will forge important new discoveries, deliver novel therapies, and help even more children thrive.